



Experience with introduction of AI in Breast Cancer Screening in Capital Region of Denmark

**Danske kræftforskningsdage
2023**

Ilse Vejborg,
Chief Physician and Head of Capital Mammography Screening Programme, Capital Region, DK
Chairman DFRM, Chairman DKMS



Experience with introduction of AI in Breast Cancer Screening in Capital Region of **Nothing to disclose**

Ilse Vejborg,
Chief Physician and Head of Capital Mammography Screening Programme, Capital Region, DK
Chairman DFRM, Chairman DKMS

Retrospective Simulation Studies

A collaboration between two Institutes at University of Copenhagen (Computerscience and Public Health), a professor and founder of the AI from Radboud University, NL and Capital Mammography Screening Programme



Two retrospective simulation studies based on

- Results of Double blind readings by experienced full time breast radiologist of 114.421 consecutive womens screening exams versus AI
- Sampling period January 2014 - December 2015. 2 year follow up.
- 791 screen detected cancers, 327 interval cancers and 2107 false positives

Preliminary simulation study:

AI only (no radiologist readings) with a sensitivity matched to experienced breast radiologists sensitivity

- 100% work load reduction
- Lower specificity than the radiologist (94.9% versus 98.1%)
- Signifikant rise in FP: 276,5% rise - 5825 women compared to 2107

"An Artificial-Intelligence-based Mammography Screening Protocol for Breast Cancer: Outcome and Radiologist Workload". Radiology 2022.

Retrospective simulation studies



Main simulation study:


- AI[★] only reader on the lowest risk group (<5 on a risk score on a scale from 1-10)
- Double blind readings by experienced breast radiologists (risk score ≥ 5 - 9,989)
- Direct recall of women with a risk score on ≥ 9.989

Results

- Sensitivity: AI 69.7% versus breast radiologist 70.8%
- Specificity: AI 98.6% versus breast radiologist 98.1%
- Numbers of false positive reduced with 25%

★Transpara version 1.7.0

"An Artificial-Intelligence-based Mammography Screening Protocol for Breast Cancer: Outcome and Radiologist Workload". Radiology 2022.




Implementation of AI in Capital Mammography Screening Programme in Denmark

Main goal has been to reduce radiologist workload keeping quality indicators stable

Screening mammography

- 2 standardized views: CC + MLO
- No clinical examination or UL




Time consumption

- *6-10 minutes in the examination room at the screening clinics (radiographers)*
- **1-3 min. x 2/ exam** (when the systems are working) **centralized double blind readings** (two radiologists)

Screening mammography

- 2 standardized views: CC + MLO
- No clinical examination



Hard competition but..

Target group in DK ≥ 700.000 Q aged 50-69 år; 220.000 Q in RegionH

Time consumption
6-10 minutes in the
Centralized double

Extended offer to breast cancer treated women aged 70-79 years; 8150 Q in Capital Region

s are working)

5 Screening Clinics in Capital Region, DK



Mammograms analyzed by Transpara AI


Local regional score

Selection of highest regional score

Stratification into **risk categories on a scale from 1-100**

Shown in PACS

(in the end of the exam)



R ML0
FFDM




L ML0
FFDM



**Highest regional score decides
the final risk score**

R CC
FFDM



L CC
FFDM

Risiko baseret på tilstedeværelsen af abnormiteter

Forhøjet

Højeste lokaliserede score

95

transpara[®] report

By ScreenPoint Medical

Alle til præsentation

Version 1.0.0

Relation between scores

Capital Region:
Score 78 = recall rate på 2,5%

3th of May 2022 AI first reader
of whole low risk group

18th of November 2021



| Højeste lokaliserede score ved undersøgelse | Risiko baseret på tilstedeværelsen af abnormiteter | Transpara Undersøgelsesresultat |
|---|---|----------------------------------|
| ≥ 75 | Forhøjet - 1 ud af 10 undersøgelser påviser kræft ved screening* - Svarer til en tilbagekaldelsesrate på 4%* | 10 Tjek lokaliseret score |
| 61 - 74 | Middel Samlet frekvens for kræft i dette interval svarer til screeningen af befolkningen (6/1000) | 9 |
| 50 - 60 | | 8 |
| 43 - 49 | | 7 |
| 39 - 42 | Lav - > 99,9% normale test* - Fund vist med markør ≥ 36 | 6 |
| 36 - 38 | | ≤ 5 |
| ≤ 35 | | |

}

≥ 70%


R MLO
FFDM



L MLO
FFDM

AI has no previous exams to compare with- but the radiologists have them!

R CC
FFDM



L CC
FFDM



Risiko baseret på tilstedeværelsen af abnormiteter

Forhøjet

Højeste lokaliserede score

95

transpara[®] report

By ScreenPoint Medical

Alle AI-prøver gennemgås

Version 1.0

Workflow in Capital Region DK

AI+Single or double reading?

Women with **low risk score**

from 3/5 2022 all with score ≤ 42 (<36 from 18/11 2021-3/5 2022)



AI (first reader) + one breast radiologist (second reader)

Consensus list in case of disagreement

Allways a radiologist who decide!

Women with **intermediate or high risk score**



Double blind readings as usual by two breast radiologists (with AI assistance)

(no direct recall)

Performance Indicators

(Danish Quality Database for Mammography Screening)

| Performance Indicator (Number) | Invitation round | | | | | |
|--|-----------------------------|------------------------|---------------------------|----------------------------|--------------------|--------------------|
| | First 2008- 2009/2010 | Second 2010-2011/12 | Third 2012- 2013/14 | Fourth 2014- 2015/16 | Fifth 2016-2018 | Sixth 2018-2020 |
| 2 a. Participation (%invited) | 76% | 82% | 84% | 83% | 83% | 84% |
| b. Coverage (% target) | 75% | 75% | 77% | 76% | 79% | 79% |
| 4. Recall rate | 3% | 2,7% | 2,7% | 2,5% | 2,4% | 2,4% |
| False-positive rate | 2.0% | 2.1% | 2.1% | 1.9% | 1,8% | 1,8% |
| Detection rate (IC+DCIS) | 0.93% | 0.62% | 0.67% | 0.61% | 0.62% | 0,61% |
| 5. Interval cancer rate (Interval IC / Interval IC+ screen detected < 12 / 12-24 months after) | NA | NA | 12% 21% | 11% 19% | 11% 20% | 13% 21% |
| 6. Invasive % (IC / IC+DCIS) | 87% | 86% | 86% | 86% | 87% | 85% |
| 7. Lymph node neg % | 70% | 75% | 78% | 81% | 76% | 77% |
| 8. Small tumor ≤1cm % | 37% | 39% | 37% | 37% | 37% | 37% |
| 9. Benign : malign operation ratio | 1:6 | 1:7 | 1:8 | 1:9 | 1:10,5 | 1:10 |
| 10.BCS % (BCS / BCS+ mastectomy) | 80% | 81% | 83% | No longer in use | Not in use | Not in use |

http://www.rkkp.dk/siteassets/om-rkkp/de-kliniske-kvalitetsdatabaser/mammografiscreening/dkms-rapport-version-52_51113.pdf

https://www.sundhed.dk/content/cms/78/4678_dkms-rapport-2016-7-version.pdf

https://www.sundhed.dk/content/cms/78/4678_dansk-kvalitetsdatabase-for-mammografi-screening-rapport-2017.pdf

The Danish National Mammography Screening program 2008-2020

Performance Indicators

| Performance Indicator (Number) | Invitation round | | | | | |
|--|-----------------------------|------------------------|---------------------------|----------------------------|--------------------|--------------------|
| | First 2008- 2009/2010 | Second 2010-2011/12 | Third 2012- 2013/14 | Fourth 2014- 2015/16 | Fifth 2016-2018 | Sixth 2018-2020 |
| 2 a. Participation (%invited) | 76% | 82% | 84% | 83% | 83% | 84% |
| b. Coverage (% target) | | | | | | |
| 4. Recall rate | | | | | | |
| False-positive rate | | | | | | |
| Detection rate (IC+DCIS) | | | | | | |
| 5. Interval cancer rate (Interval IC / Interval IC+ screened detected < 12 / 12-24 months a) | | | | | | |
| 6. Invasive % (IC / IC+DCIS) | | | | | | |
| 7. Lymph node neg % | 70% | 75% | 78% | 81% | 76% | 77% |
| 8. Small tumor ≤1cm % | 37% | 39% | 37% | 37% | 37% | 37% |
| 9. Benign : malign operation ratio | 1:6 | 1:7 | 1:8 | 1:9 | 1:10,5 | 1:10 |
| 10.BCS % (BCS / BCS+ mastectomy) | 80% | 81% | 83% | No longer in use | Not in use | Not in use |

Even a small increase in recall rate decrease the benefit!

1 diagnostic mammography (incl. clinical examination, UI and evt. needle biopsy) matches = 30-50 single readings

http://www.rkkp.dk/siteassets/om-rkkp/de-kliniske-kvalitetsdatabaser/mammografiscreening/dkms-rapport-version-52_51113.pdf

https://www.sundhed.dk/content/cms/78/4678_dkms-rapport-2016-7-version.pdf

https://www.sundhed.dk/content/cms/78/4678_dansk-kvalitetsdatabase-for-mammografi-screening-rapport-2017.pdf

NA: not available

Conclusion



- Background for implementation: Very promising results in our large retrospective simulations study
- Prospective results:
 - AI is a valuable tool for risk stratification on basis of analysis of the mammograms ($\geq 70\%$ stratified as low risk)
 - Substantial workload reduction in readings for breast radiologists ($\geq 35\%$)
 - $\geq 20\%$ reduction in recalls
 - Early quality indicators shows at least as good results as previously

Thank you for your attention!

